CAR-T Meeting 2020 | ZUMA series update: ZUMA-1 and ZUMA-2
Marie José Kersten, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, outlines the ZUMA-2 trial (NCT02601313), a phase II study evaluating the efficacy of KTE-X19 in patients with relapsed/refractory (R/R) mantle cell lymphoma. Additionally, Prof. Kersten discusses a comparison of ZUMA-1 (NCT02348216) and SCHOLAR-1 studies and highlights the importance of real world data. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
Get great new content delivered to your inboxSign up